30/01/23 General Grey Wolf Therapeutics Closes Oversubscribed $49 Million Series B Financing to Advance First-of...
25/01/23 General Planning permission granted for the latest phase of development at Oxford Technology Park
24/01/23 General FDA accepts Drug Master File, signifying a new milestone for Touchlight’s enzymatic doggybone D...